The role of inflammation in DME

Article

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

Hideharu Funatsu, MD of the Tokyo Women's Medical University, Japan and colleagues conducted a retrospective case-control study of DME patients (n=53), patients with non-diabetic ocular disease (n=15) and diabetic patients who were free of retinopathy (n=8). The team examined samples of the vitreous fluid to determine levels of inflammatory factors, specifically vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and pigment epithelium-derived factor (PEDF).

The researchers found that DME patients demonstrated significantly higher levels of VEGF, ICAM-1, IL-6 and MCP-1 when compared with other patient groups, although the level of PEDF was significantly lower in the vitreous of DME patients when compared with other patient groups. In addition, the levels of each of these inflammatory factors in the vitreous were associated with the thickness of the retina at the central fovea. VEGF and ICAM-1 had a greater influence on the severity of DME than IL-6, MCP-1 or PEDF.

The team concluded that the level of these inflammatory factors - particularly VEGF and ICAM-1 - in the vitreous correlate significantly to the permeability of the retina and the severity of DME.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.